3 completed, 3 unknown, 1 active not recruiting, 1 recruiting. 3 Phase 3, 2 Not applicable, 2 Phase 2, 2 Phase 4, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Completed 1, Terminated 1, Unknown 1 |
| Not applicable | 2 | Completed 1, Recruiting 1 |
| Phase 2 | 2 | Completed 1, Withdrawn 1 |
| Phase 4 | 2 | Active not recruiting 1, Unknown 1 |
| Phase 1 | 1 | Unknown 1 |
Follow Coat Protein Complex I: new trials by email Literature Review of Coat Protein Complex I trials Research Report on Coat Protein Complex I
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Genetic Variation in TRAF3IP2 (rs13190932) Methotrexate - Psoriasis, Psoriatic Arthritis | Not applicable | Recruiting | South Valley University | 50 | 2025-06-01 | 2025-07-25 |
| Study to Evaluate Oral BIIB061 Added to Interferon-beta1 (IFN-β1) or Glatiramer Acetate in Relapsing Multiple Sclerosis (RMS) Placebo, BIIB061, Interferon-beta1 - Relapsing Multiple Sclerosis | Phase 2 | Withdrawn | Biogen | 2021-06-30 | 2023-06-01 | |
| A Window of Opportunity Trial of Intratumoral Injection of Copaxone® in Patients With Percutaneously Accessible Tumors Copaxone - Cutaneous Squamous Cell Carcinoma, Squamous Cell Carcinoma | Phase 1 | Unknown | University of Kansas Medical Center | 10 | 2019-07-26 | 2023-05-19 |
| Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS Early Highly Effective Therapies Group, Escalation Therapies Group - Multiple Sclerosis, Relapsing-Remitting | Phase 4 | Active not recruiting | The Cleveland Clinic | 800 | 2019-01-03 | 2026-08-31 |
| Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial Natalizumab/natalizumab-sztn, Alemtuzumab, Ocrelizumab, Rituximab/rituximab-arrx/rituximab-abbs/rituximab-pvvr, Cladribine, Ofatumumab, Ublituximab-xiiy, Ocrelizumab and hyaluronidase-ocsq, Glatiramer acetate, Interferons (intramuscular, subcutaneous, pegylated) Teriflunomide, Fumarates (dimethyl, diroximel, monomethyl) Fingolimod, Siponimod, Ozanimod, Ponesimod - Multiple Sclerosis, Relapsing-Remitting | Not applicable | Completed | Johns Hopkins University | 900 | 2018-05-02 | 2026-09-23 |
| MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone fingolimod, glatiramer acetate - Relapsing-remitting Multiple Sclerosis (RRMS) | Phase 3 | Terminated | Novartis Pharmaceuticals | 1064 | 2012-08-09 | 2019-05-28 |
| Comparison of Rituximab Induction Therapy Followed by Glatiramer Acetate Rituximab, Glatiramer Acetate, Placebo - Multiple Sclerosis | Phase 2 | Completed | University of Colorado, Denver | 53 | 2012-02-01 | 2018-06-08 |
| Investigating the Neuroprotective Effect of Cop-1 (Copaxone) in Acute Primary Angle Closure Copaxone, Placebo (buffered normal saline w/v) - Glaucoma, Angle-closure, Primary, Acute | Phase 3 | Unknown | Singapore Eye Research Institute | 196 | 2010-09-01 | 2013-09-06 |
| Effects of Copaxone in the Retinal Function in Diabetic Patients After Panphotocoagulation Glatiramer acetate (Copaxone), Mannitol - Diabetic Retinopathy | Phase 4 | Unknown | Federal University of São Paulo | 30 | 2006-07-01 | 2008-05-14 |
| Phase III Randomized, Double-Blind, Placebo-Controlled Study of Copolymer 1 for Relapsing-Remitting Multiple Sclerosis copolymer 1 - Multiple Sclerosis | Phase 3 | Completed | National Center for Research Resources (NCRR) | 250 | 1991-10-01 | 2005-06-24 |
Multiple Sclerosis, Relapsing-Remitting (3) · Multiple Sclerosis (2) · Arthritis, Psoriatic (1) · Carcinoma, Basal Cell (1) · Carcinoma, Squamous Cell (1) · Diabetic Retinopathy (1) · Glaucoma (1) · Mental Disorders (1) · Neurologic Manifestations (1) · Psoriasis (1) · Rare Diseases (1)
Biogen (1) · Federal University of São Paulo (1) · Johns Hopkins University (1) · National Center for Research Resources (NCRR) (1) · Novartis Pharmaceuticals (1) · Singapore Eye Research Institute (1) · South Valley University (1) · The Cleveland Clinic (1) · University of Colorado, Denver (1) · University of Kansas Medical Center (1)
United States (5) · Brazil (2) · Argentina (1) · Canada (1) · Chile (1) · Egypt (1) · Mexico (1) · Puerto Rico (1) · Singapore (1) · United Kingdom (1)
Augusto Paranhos Jr, MD (1) · Daniel Ontaneda, MD, MSc (1) · Eisa Mohammed Hegazy, Professor (1) · Ellen M. Mowry, MD, MCR (1) · Joaquina Baranda, MD (1) · Kenneth P. Johnson (1) · Nikos Evangelou, MD, DPhil (1) · Scott D. Newsome, DO (1) · Timothy Vollmer, MD (1) · Tin Aung, FRCOphth,PhD (1)
PMID 30635477, PMID 32852530, PMID 38654416, PMID 40230575, PMID 42218617
2019 (1)